Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Eledon Pharmaceuticals (NASDAQ: ELDN) has announced its participation in the upcoming Cantor Global Healthcare Conference. The company's CEO, David-Alexandre C. Gros, M.D., will engage in a fireside chat on Wednesday, September 18, 2024, at 8:35 a.m. ET.
Interested parties can register in advance for the webcast of the fireside chat. For those unable to attend live, a replay of the webcast will be made available on the company's website in the Events section following the session. This presentation at a major healthcare conference provides an opportunity for Eledon to showcase its developments and engage with industry professionals and investors.
Eledon Pharmaceuticals (NASDAQ: ELDN) ha annunciato la sua partecipazione alla prossima Cantor Global Healthcare Conference. Il CEO dell'azienda, David-Alexandre C. Gros, M.D., parteciperà a una chiacchierata informale mercoledì 18 settembre 2024, alle 8:35 ET.
Le parti interessate possono registrarsi in anticipo per la trasmissione in diretta della chiacchierata. Per coloro che non possono partecipare live, sarà disponibile una registrazione della trasmissione sul sito web dell'azienda nella sezione Eventi dopo la sessione. Questa presentazione in una conferenza sanitaria di alto livello offre a Eledon l'opportunità di mostrare i propri sviluppi e interagire con professionisti del settore e investitori.
Eledon Pharmaceuticals (NASDAQ: ELDN) ha anunciado su participación en la próxima Cantor Global Healthcare Conference. El CEO de la compañía, David-Alexandre C. Gros, M.D., participará en una charla íntima el miércoles 18 de septiembre de 2024, a las 8:35 a.m. ET.
Las partes interesadas pueden registrarse con anticipación para la transmisión en vivo de la charla. Para aquellos que no puedan asistir en directo, se pondrá a disposición una repetición de la transmisión en el sitio web de la empresa en la sección de Eventos después de la sesión. Esta presentación en una importante conferencia de salud ofrece a Eledon la oportunidad de mostrar sus desarrollos y relacionarse con profesionales de la industria e inversores.
Eledon Pharmaceuticals (NASDAQ: ELDN)은 다가오는 Cantor Global Healthcare Conference에 참여할 것이라고 발표했습니다. 회사의 CEO인 David-Alexandre C. Gros, M.D.는 2024년 9월 18일 수요일 오전 8시 35분 ET에 화상 대화에 참여할 예정입니다.
관심 있는 분들은 화상 대화의 웹캐스트를 사전 등록할 수 있습니다. 실시간 참석이 불가능한 경우, 세션 이후 회사 웹사이트의 이벤트 섹션에서 웹캐스트의 재생을 이용하실 수 있습니다. 주요 의료 회의에서의 이번 발표는 Eledon이 자신의 발전을 선보이고 업계 전문가 및 투자자와 소통할 수 있는 기회를 제공합니다.
Eledon Pharmaceuticals (NASDAQ: ELDN) a annoncé sa participation à la prochaine Cantor Global Healthcare Conference. Le PDG de l'entreprise, David-Alexandre C. Gros, M.D., participera à une discussion informelle le mercredi 18 septembre 2024, à 8h35 ET.
Les parties intéressées peuvent s'inscrire à l'avance pour le webcast de la discussion. Pour ceux qui ne peuvent pas assister en direct, une rediffusion du webcast sera disponible sur le site web de l'entreprise dans la section Événements après la session. Cette présentation lors d'une grande conférence en santé offre à Eledon l'occasion de mettre en avant ses développements et d'engager le dialogue avec des professionnels du secteur et des investisseurs.
Eledon Pharmaceuticals (NASDAQ: ELDN) hat seine Teilnahme an der bevorstehenden Cantor Global Healthcare Conference angekündigt. Der CEO des Unternehmens, David-Alexandre C. Gros, M.D., wird an einem Fireside-Chat am Mittwoch, den 18. September 2024, um 8:35 Uhr ET teilnehmen.
Interessierte Parteien können sich im Voraus für das Webcast des Fireside-Chats registrieren. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung des Webcasts nach der Sitzung im Bereich Veranstaltungen der Unternehmenswebsite verfügbar sein. Diese Präsentation auf einer großen Gesundheitskonferenz bietet Eledon die Möglichkeit, seine Entwicklungen zu zeigen und mit Branchenprofis und Investoren in Kontakt zu treten.
- None.
- None.
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET.
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com
Source: Eledon Pharmaceuticals
FAQ
When is Eledon Pharmaceuticals (ELDN) presenting at the Cantor Global Healthcare Conference?
Who will be representing Eledon Pharmaceuticals (ELDN) at the Cantor Global Healthcare Conference?
How can I watch Eledon Pharmaceuticals' (ELDN) presentation at the Cantor Global Healthcare Conference?
What type of presentation will Eledon Pharmaceuticals (ELDN) give at the Cantor Global Healthcare Conference?
